Renflexis®

INN: infliximab

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Biosimilar

Delivery Route

Intravenous Infusion

Health Canada Approval

2017

Storage

Only a healthcare professional should prepare and administer this medicine.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

Infants may be at increased risk for infection.

Breastfeeding Indication

Low exposure levels due to degradation by GI tract.

Pediatric Indication

Authorized for pediatric patients with Crohn’s disease ≥9 years old or with ulcerative colitis ≥6 years old.

Learn More

View the Renflexis® product monograph.